Cytokine therapy after bone marrow transplantation

Pharmacotherapy

Volumn 16, Issue 4, 1996, Pages 593-608

  Dix, Suzanne P ^a   Gilmore, Claire E ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

BONE MARROW PURGING; BONE MARROW TRANSPLANTATION; DOSE CALCULATION; DRUG INFORMATION; DYSPNEA; FLUSHING; GRAFT FAILURE; HUMAN; HYPOTENSION; HYPOXEMIA; HYPOXIA; INTRAVENOUS DRUG ADMINISTRATION; REVIEW; SYNCOPE; VOMITING;

BONE MARROW TRANSPLANTATION; CLINICAL TRIALS, PHASE III; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS;

EID: 0029842112     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Morstyn G, Lieschke GJ, Sheridan W, et al. Pharmacology of the colony stimulating factors. Trends Pharmacol Sci 1989;10:154-9.
2. Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther 1993;15(1):19-29.
3. Lieschke GJ, Ceon J, Morstyn G. Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:2634-43.
4. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1994;12: 2471-2508.
5. Brandt S, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988;318:869-76.
6. Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988;72:834-6.
7. O'Day ST, Rabinowe SN, Neuberg D, et al. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood 1994;83: 2707-14.
8. Peters WP, Kurtzberg J, Atwater S, et al. Comparative effects of rHuG-CSF and rHuGM-CSF on hematopoietic reconstitution and granulocyte function after high dose chemotherapy and autologous bone marrow transplantation (ABMT) [abstr]. Proc Am Soc Clin Oncol 1989;8:181.
9. Taylor KM, Jagannath S, Spitzer G, et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989;7:1791-9.
10. Spitzer G, Deisseroth A, Ventura G, et al. Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy. Int J Cell Cloning 1990;8(suppl 1):249-61.
11. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-4.
12. Link H, Boogaerts M, Carella A, et al. A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 1992;80:2188-95.
13. Nemunaitis J, Rabinowe S, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer N Engl J Med 1991;324:1773-8.
14. Khwaja A, Linch DC, Goldstone AH, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British national lymphoma investigation double-blind, placebo-controlled trial. Br J Haematol 1991;82:317-23.
15. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann Intern Med 1992;116:177-82.
16. Gorin NC, Coiffier B, Hayat M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial Blood 1992;80:1149-57.
17. Stahel RA, Jost LM, Cerny T, et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931-8.
18. Schmitz N, Dreger P, Zander AR, et al. Results of a randomized, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15:261-6.
19. Blaise D, Vernant JP, Fiere D, et al. A randomised, controlled, multicentre trial of recombinant human granulocyte colony stimulating factor (filgrastim) in patients treated by bone marrow transplantation (BMT) with total body irradiation (TBI) for acute lymphoblastic leukemia (ALL) or lymphoblastic leukemia (LL) [abstr]. Blood 1992;80(suppl 1):982a.
20. Rabinowe SN, Neuberg D, Bierman PJ, et al. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 1993;81:1903-8.
21. Nemunaitis J. Granulocyte-macrophage-colony-stimulating factor: a review from preclinical development to clinical application. Transfusion 1993;33(1):70-83.
22. Peters WP, Stuart A, Affronti ML, Kim CS, Coleman RE. Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 1988;72:1310-15.
23. Toner CG, Jakubowski AA, Crown JP, Meisenberg B, Sheridan C, Gabrilove JL. Colony-stimulating factors and neutrophil migration [letter]. Ann Intern Med 1989;110: 846-7.
24. Nemunaitis J, Singer JW, Buckner CD, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990;76(1):245-53.
25. Advani R, Chao NJ, Horning SJ, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992;116:183-9.
26. Blazar BR, Kersey JH, McGlave PB, et al. In vivo administration of recombinant human granulocyte/macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989;73:849-57.
27. Carlo-Stella C, Mangoni L, Almici C, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in patients with lymphoid malignancies transplanted with unpurged or adjusted-dose mafosfamide-purged autologous marrow. Blood 1992;80:2412-18.
28. Schriber JR, Negrin RS, Chao NJ, et al. The efficacy of granulocyte colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow. Leukemia 1993;7:1491-5.
29. Kennedy MJ, Davis J, Passos-Coelho, J et al. Administration of human granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery after high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. Cancer Res 1993;53:5424-8.
30. Stone RM, Beig DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995;332:1671-7.
31. Drombert H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995;332:1678-83.
32. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the eastern cooperative oncology group (E1490). Blood 1995;86:457-62.
33. Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet 1990;336: 1417-20.
34. De Witte T, Gratwohl A, Van Der Lely N, et al. A multicentre double blind randomised trial of recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) in recipients of allogeneic T-cell depleted bone marrow [abstr]. Blood 1990;76:139a.
35. Nemunaitis J, Rosenfield CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rh GM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995;15:949-54.
36. Masoaka T, Takaku F, Kato S, et al. Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Exp Hematol 1989;17:1047-50.
37. Schriber JR, Chao NJ, Long GD, et al. Granulocyte colony stimulating factor after allogeneic bone marrow transplantation. Blood 1994;84(5):1680-4.
38. Nemunaitis J, Anasetti C, Storb R, et al. Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 1992;79(10):2572-7.
39. Anasetti C, Anderson G, Appelbaum FR, et al. Phase III study of rhGM-CSF in allogeneic marrow transplantation from unrelated donors [abstr]. Blood 1993;82(suppl 1):454a.
40. Nemunaitis J, Buckner CD, Appelbaum FR, et al. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1991;77:2065-71.
41. Weisdorf DJ, Verfaillie CM, Davies SM, et al. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF. Blood 1995;85:3452-6.
42. Steward WP, Scarffe JH, Bonnem E, Crowther E. Clinical studies with recombinant granulocyte-macrophage colony stimulating factor. Int J Cell Cloning 1990;8(suppl 1):335-46.
43. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, et al. Abrogating chemotherapy induced myelosuppression by recombinant granulocyte-macrophage colony stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992;10(8):1266-77.
44. Hovgaard DJ, Nissen NI. Effect of recombinant human granulocyte-macrophage colony stimulating factor in patients with Hodgkin's disease: a phase I/II study. J Clin Oncol 1992;10(3):390-7.
45. Gerhartz HH, Stern AC, Wolf-Hornung B, et al. Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy. Leukemia Res 1993;17(2):175-85.
46. Linch DC, Scarffe H, Proctor S, et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993;11:307-11.
47. Kodo H, Tajika K, Takahashi S, et al. Acceleration of neutrophilic granulocyte recovery after bone marrow transplantation by administration of recombinant human granulocyte colony-stimulating factor. Lancet 1988;2:38-9.
48. Eguchi K, Sasaki S, Tamura T, et al. Dose escalation study of recombinant human granulocyte colony stimulating factor (KRN8601) in patients with advanced malignancy. Cancer Res 1989;49:5221-4.
49. Kitayama H, Ishikawa J, Yamagami T, et al. Granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Jpn J Clin Oncol 1989;19(4):367-72.
50. Miller JA, Beveridge RA. A comparison of efficacy of GM-CSF versus G-CSF in the therapeutic setting of chemotherapy induced neutropenia [abstr]. Blood 1994;84(suppl 1):22a.
51. Beveridge RA, Kales AN, Binder RA, Robert NJ, Miller JA. Comparison of toxicities of G-CSF and yeast derived GM-CSF [abstr]. Blood 1993;82(suppl 1):495a.
52. Neidhart JA, Mangalik A, Stidley CA, et al. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy. J Clin Oncol 1992;10(9): 1460-9.
53. Immunex Corporation. Leukine (sargramostim) package insert. Seattle, WA; 1992.
54. Amgen Inc. Neupogen (filgrastim) package insert. Thousand Oaks, CA; 1994.
55. Dix SP, Devine S, Reynolds RC, et al. Influence of G-CSF on regimen-associated toxicities in patients undergoing autologous bone marrow transplantation for breast cancer [abstr]. Blood 1992;80(10, suppl 1):522a.
56. Lindley C. Update on colony-stimulating factors. Highlights on Antineoplastic Drugs 1994;12(2):24-31.
57. Meropol NJ, Miller LL, Korn EI, et al. Severe myelosuppression resulting from concurrent administration of granulocyte-colony stimulating factor in cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201-3.
58. Ikebuchi K, Ihle JN, Hirai Y, et al. Synergistic factors for stem cell proliferation: further studies of the target stem cells and the mechanism of stimulation by IL-1, IL-6, and G-CSF. Blood 1988;72:2007-14.
59. Aurer I, Ribas A, Gale RP. What is the role of colony stimulating factors in bone marrow transplantation? Bone Marrow Transplant 1990;6:79-87.
60. Khwaja A, Mills W, Leveridge K, Goldstone AH, Linch DC. Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT. Bone Marrow Transplant 1993;11:479-82.
61. Vey N, Molnar S, Faucher C, et al. Delayed administration of granulocyte colony-stimulating factor after autologous bone marrow transplantation: effect on granulocyte recovery. Bone Marrow Transplant 1994;14:779-82.
62. Morstyn G, Lieschke GJ, Sheridan W, et al. Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor. Semin Hematol 1989;26(suppl 2):9-13.
63. Glaspy JA, Jakway J. Cost considerations in therapy with myeloid growth factors. Am J Hosp Pharm 1993;50(suppl 3):S19-26.
64. Bleecker GC. Reimbursement and pharmacoeconomic perspectives in biotechnology. Am J Hosp Pharm 1993; 50(suppl 3):S27-30.
65. Petros WP, Peters WP. Cost implications of haematopoietic growth factors in the BMT setting. Bone Marrow Transplant 1993;11(suppl 2):36-8.
66. Finley RS. Measuring the cost-effectiveness of hematopoietic growth factor therapy. Cancer 1991;67:2727-30.
67. Jonsson B, Karlsson G. Outcome measurement in economic evaluations of growth factors. Eur J Cancer 1993;29A(suppl 7):S19-22.
68. Luce BR, Singer JW, Weschler JM, et al. Recombinant human granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. Pharmacoeconomics 1994;6(1):42-8.